Pear VC

Portal is a cell engineering platform firm that enables next generation cell engineering and cell analytics in research and clinical settings.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Valar Labs, founded in 2021 by Anirudh Joshi, Viswesh Krishna, Pranav Rajpurkar, and Damir Vrabac, is a healthcare technology company focused on enhancing cancer treatment through the use of artificial intelligence. The company has developed a software platform that analyzes imaging data, which is routinely collected in clinical settings, to provide oncologists with interpretable and actionable insights. By leveraging patient-specific characteristics, Valar Labs aims to support oncologists in making informed treatment decisions, ultimately improving patient outcomes in cancer care.

Portal is a cell engineering platform firm that enables next generation cell engineering and cell analytics in research and clinical settings.

Range Biotechnologies develops translational proteomics tools to enable personalized health by precisely measuring multiple proteins across numerous samples, delivering insights into the mechanisms of disease and their evolution over time to support healthcare professionals.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Range Biotechnologies develops translational proteomics tools to enable personalized health by precisely measuring multiple proteins across numerous samples, delivering insights into the mechanisms of disease and their evolution over time to support healthcare professionals.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

Valar Labs, founded in 2021 by Anirudh Joshi, Viswesh Krishna, Pranav Rajpurkar, and Damir Vrabac, is a healthcare technology company focused on enhancing cancer treatment through the use of artificial intelligence. The company has developed a software platform that analyzes imaging data, which is routinely collected in clinical settings, to provide oncologists with interpretable and actionable insights. By leveraging patient-specific characteristics, Valar Labs aims to support oncologists in making informed treatment decisions, ultimately improving patient outcomes in cancer care.

Axle Health specializes in software for home healthcare providers. Its platform offers scheduling, workforce management, patient engagement, and logistics optimization tools. Integrated with various EMRs, Axle's customizable solutions improve clinical team utilization and automate operational tasks.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Axle Health specializes in software for home healthcare providers. Its platform offers scheduling, workforce management, patient engagement, and logistics optimization tools. Integrated with various EMRs, Axle's customizable solutions improve clinical team utilization and automate operational tasks.

Axle Health specializes in software for home healthcare providers. Its platform offers scheduling, workforce management, patient engagement, and logistics optimization tools. Integrated with various EMRs, Axle's customizable solutions improve clinical team utilization and automate operational tasks.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

ixLayer is a leader in the health-tech sector, specializing in precision health testing solutions that facilitate virtual health testing for various stakeholders, including health systems, payors, biopharma, and health-focused organizations. Established in 2018, ixLayer's platform offers comprehensive solutions encompassing technical, security, regulatory, and user experience aspects of complex health testing. As the demand for remote and virtual care continues to grow, ixLayer enhances patient engagement and preventative health strategies by enabling real-time health and wellness lab testing. The platform can be seamlessly integrated with existing patient engagement systems and portals, allowing organizations to efficiently launch and manage testing programs. Serving millions of patients, ixLayer has developed and implemented numerous testing initiatives for large organizations, healthcare systems, and government agencies, contributing to a progressive shift towards telehealth.

Polygon, founded in 2019 and headquartered in Los Angeles, California, focuses on providing remote diagnostic services for individuals with learning differences such as dyslexia and ADHD. The company employs licensed psychologists to conduct comprehensive self-assessments, delivering personalized reports that include diagnoses and intervention strategies. Polygon's mission is to equip individuals with the necessary tools for success, ranging from initial diagnosis to ongoing support, thereby enhancing their capacity to thrive in educational environments.

Foresight Diagnostics develops a novel liquid biopsy test to measure minimal residual disease in cancer patients. This aids in patient management and has garnered significant interest from pharmaceutical companies.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Polygon, founded in 2019 and headquartered in Los Angeles, California, focuses on providing remote diagnostic services for individuals with learning differences such as dyslexia and ADHD. The company employs licensed psychologists to conduct comprehensive self-assessments, delivering personalized reports that include diagnoses and intervention strategies. Polygon's mission is to equip individuals with the necessary tools for success, ranging from initial diagnosis to ongoing support, thereby enhancing their capacity to thrive in educational environments.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

Xilis, Inc. is a biotechnology company founded in 2019 and based in Chapel Hill, North Carolina. The company specializes in developing next-generation organoid technologies aimed at guiding precision therapy for cancer patients and enhancing drug discovery processes. Its flagship platform, XilisµO, facilitates rapid diagnostics, personalized drug screening, and the creation of scalable patient-derived models, which support high-throughput drug discovery. By enabling both physicians and pharmaceutical companies to conduct tailored drug screenings, Xilis aims to lower costs and improve treatment outcomes for cancer patients.

ixLayer is a leader in the health-tech sector, specializing in precision health testing solutions that facilitate virtual health testing for various stakeholders, including health systems, payors, biopharma, and health-focused organizations. Established in 2018, ixLayer's platform offers comprehensive solutions encompassing technical, security, regulatory, and user experience aspects of complex health testing. As the demand for remote and virtual care continues to grow, ixLayer enhances patient engagement and preventative health strategies by enabling real-time health and wellness lab testing. The platform can be seamlessly integrated with existing patient engagement systems and portals, allowing organizations to efficiently launch and manage testing programs. Serving millions of patients, ixLayer has developed and implemented numerous testing initiatives for large organizations, healthcare systems, and government agencies, contributing to a progressive shift towards telehealth.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

ImpriMed, Inc. is a biotechnology company focused on providing personalized drug response prediction services for veterinary oncology. Established in 2017 and headquartered in Palo Alto, California, with an additional office in Seoul, South Korea, the company specializes in analyzing the drug responses of live cancer cells from pets, particularly in cases of lymphoma. By collecting genetic and cellular information from these cancer cells, ImpriMed develops precision medicine techniques that assist veterinary oncologists in selecting the most effective anticancer treatments for individual pets. This patient-derived database not only enhances treatment decisions for animals but also has the potential to translate insights into human oncology, ultimately aiding in the development of tailored cancer therapies for humans.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

Viz.ai, Inc. specializes in healthcare imaging software designed to enhance stroke care through the use of artificial intelligence. The company's flagship technology synchronizes treatment by reducing delays in patient care, enabling rapid identification of large vessel occlusion (LVO) strokes using advanced deep learning algorithms. Key offerings include Viz LVO, which alerts on-call stroke teams based on CT angiogram images, and Viz CTP, which analyzes CT perfusion images and generates critical parametric data. Additionally, Viz HUB facilitates communication among clinical teams to coordinate care efficiently, while Viz VIEW allows healthcare professionals to view imaging data on mobile devices. Founded in 2016 and headquartered in San Francisco, the company aims to transform healthcare delivery by improving the speed and accessibility of treatment for stroke patients.

Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.

Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.

Axle Health specializes in software for home healthcare providers. Its platform offers scheduling, workforce management, patient engagement, and logistics optimization tools. Integrated with various EMRs, Axle's customizable solutions improve clinical team utilization and automate operational tasks.